$1.69
0.60% yesterday
Nasdaq, Sep 27, 10:00 pm CET
ISIN
US92511W1080
Symbol
VRCA
Sector
Industry

Verrica Pharmaceuticals Inc Stock price

$1.69
-0.77 31.30% 1M
-3.96 70.09% 6M
-5.63 76.91% YTD
-2.13 55.76% 1Y
-11.03 86.71% 3Y
-10.83 86.50% 5Y
-15.81 90.34% 10Y
Nasdaq, Closing price Fri, Sep 27 2024
+0.01 0.60%
ISIN
US92511W1080
Symbol
VRCA
Sector
Industry

Key metrics

Market capitalization $71.68m
Enterprise Value $86.06m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 6.19
P/S ratio (TTM) P/S ratio 5.15
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth 61.61%
Revenue (TTM) Revenue $13.91m
EBIT (operating result TTM) EBIT $-78.32m
Free Cash Flow (TTM) Free Cash Flow $-65.93m
Cash position $31.93m
EPS (TTM) EPS $-1.88
P/E forward negative
P/S forward 3.11
EV/Sales forward 3.73
Short interest 15.69%
Show more

Is Verrica Pharmaceuticals Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,901 stocks worldwide.

Verrica Pharmaceuticals Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

5 Analysts have issued a Verrica Pharmaceuticals Inc forecast:

5x Buy
100%

Analyst Opinions

5 Analysts have issued a Verrica Pharmaceuticals Inc forecast:

Buy
100%

Financial data from Verrica Pharmaceuticals Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
14 14
62% 62%
100%
- Direct Costs 2.33 2.33
118% 118%
17%
12 12
54% 54%
83%
- Selling and Administrative Expenses 69 69
336% 336%
494%
- Research and Development Expense 20 20
39% 39%
145%
-77 -77
241% 241%
-555%
- Depreciation and Amortization 1.10 1.10
36% 36%
8%
EBIT (Operating Income) EBIT -78 -78
234% 234%
-563%
Net Profit -87 -87
271% 271%
-625%

In millions USD.

Don't miss a Thing! We will send you all news about Verrica Pharmaceuticals Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Verrica Pharmaceuticals Inc Stock News

Neutral
GlobeNewsWire
24 days ago
WEST CHESTER, Pa., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Ted White, President and Chief Executive Officer of Verrica Pharmaceuticals, will participate in a fireside chat at the H.C. Wainwright 26t...
Neutral
Seeking Alpha
about one month ago
Verrica Pharmaceuticals, Inc. (NASDAQ:VRCA ) Q2 2024 Earnings Conference Call August 14, 2024 8:30 AM ET Company Participants Kevin Gardner - Managing Director, LifeSci Advisors Ted White - President and Chief Executive Officer Joe Bonaccorso - Chief Commercial Officer Terry Kohler - Chief Financial Officer Gary Goldenberg - Chief Medical Officer Conference Call Participants Stacy Ku - TD Cowen...
Neutral
GlobeNewsWire
about one month ago
- Reports YCANTH ® revenue, net of $4.9M for second quarter of 2024 along with the expansion of YCANTH's distribution footprint to include Cencora, Inc. as a specialty distributor –
More Verrica Pharmaceuticals Inc News

Company Profile

Verrica Pharmaceuticals, Inc. operates as a clinical-stage medical dermatology company, which engages in identifying, developing, and commercializing pharmaceutical products for the treatment of skin diseases. Its lead product VP-102, is a proprietary topical therapy used in common skin indications including Molluscum contagiosum and Verruca Vulgaris. The company was founded by Matthew Davidson on July 3, 2013 and is headquartered in West Chester, PA.

Head office United States
CEO Ted White
Employees 100
Founded 2013
Website www.verrica.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today